Research ArticleOriginal Article
Open Access

Utility of ferritin and inflammatory biomarkers in the diagnosis of different stages of breast cancer

Anila George, Zachariah Bobby and Biswajit Dubashi
Saudi Medical Journal August 2021, 42 (8) 825-831; DOI: https://doi.org/10.15537/smj.2021.42.8.20210244

References

  1. 1.↵
    1. Petekkaya I,
    2. Unlu O,
    3. Roach EC,
    4. Gecmez G,
    5. Okoh AK,
    6. Babacan T, et al.
    Prognostic role of inflammatory biomarkers in metastatic breast cancer. J BUON 2017; 22: 614–622.
    OpenUrl
  2. 2.↵
    1. Gauldie J,
    2. Richards C,
    3. Harnish D,
    4. Lansdorp P,
    5. Baumann H.
    Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84: 7251–7255.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Colotta F,
    2. Allavena P,
    3. Sica A,
    4. Garlanda C,
    5. Mantovani A.
    Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073–1081.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Grivennikov SI,
    2. Greten FR,
    3. Karin M.
    Immunity, inflammation, and cancer. Cell 2010; 140: 883–899.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Kabat GC,
    2. Rohan TE.
    Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007; 18: 1047–1053.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Jacobs A,
    2. Jones B,
    3. Ricketts C,
    4. Bellbrook R. D and
    5. Wangt D. Y.
    Serum ferritin concentration in early breast cancer. Br J Cancer 1976; 34: 286.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Alkhateeb AA,
    2. Han B,
    3. Connor JR.
    Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat 2013; 137: 733–744.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Asegaonkar S,
    2. Takalkar U,
    3. Kodlikeri P,
    4. Pagdhune A,
    5. Bonduliya V,
    6. Thorat A.
    Serum high sensitivity C-reactive protein in breast cancer patients. Int J Res Med Sci 2014; 2: 1408.
    OpenUrl
  9. 9.↵
    1. Kumari N,
    2. Dwarakanath BS,
    3. Das A,
    4. Bhatt AN.
    Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol 2016; 37: 11553–11572.
    OpenUrl
  10. 10.
    1. Esquivel-Velázquez M,
    2. Ostoa-Saloma P,
    3. Palacios-Arreola MI,
    4. Nava-Castro KE,
    5. Castro JI,
    6. Morales-Montor J.
    The Role of Cytokines in Breast Cancer Development and Progression. J Interferon Cytokine Res 2015; 35: 1–16.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ganz T. Hepcidin
    , a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–788.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Reuter S,
    2. Gupta SC,
    3. Chaturvedi MM,
    4. Aggarwal BB.
    Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49: 1603–1616.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Macciò A,
    2. Madeddu C,
    3. Gramignano G,
    4. Mulas C,
    5. Tanca L,
    6. Cherchi MC, et al.
    The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015; 100: 124–132.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Amrita V,P
    2. Sarkar, K
    sodavadia.Serum Iron And Ferritin As Diagnostic Marker of Breast Cancer. Natl J Integr Res Med 2018; 9: 1–6.
    OpenUrl
  15. 15.↵
    1. Ulbrich EJ,
    2. Lebrecht A,
    3. Schneider I,
    4. Ludwig E,
    5. Koelbl H,
    6. Hefler LA.
    Serum parameters of iron metabolism in patients with breast cancer. Anticancer Res 2003; 23: 5107–5109.
    OpenUrlPubMed
  16. 16.↵
    1. Deschemin JC,
    2. Vaulont S.
    Role of hepcidin in the setting of hypoferremia during acute inflammation. PLos One 2013; 8: e61050.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Sukhbaatar N,
    2. Weichhart T.
    Iron Regulation: Macrophages in Control. Pharmaceuticals (Basel) 2018; 11: 137.
    OpenUrl
  18. 18.↵
    1. Gammella E,
    2. Buratti P,
    3. Cairo G,
    4. Recalcati S.
    Macrophages: central regulators of ironbalance. Metallomics 2014; 6: 1336–1345.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Orlandi R,
    2. De Bortoli M,
    3. Ciniselli CM,
    4. Vaghi E,
    5. Caccia D,
    6. Garrisi V, et al.
    Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol 2014; 25: 352–357.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bose S,
    2. Le A.
    Glucose metabolism in cancer. Adv Exp Med Biol 2018; 1063: 3–12.
    OpenUrl
  21. 21.↵
    1. Annibaldi A,
    2. Widmann C.
    Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 2010; 13: 466–470.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Carlos AR,
    2. Weis S,
    3. Soares MP.
    Cross-talk between iron and glucose metabolism in the establishment of disease tolerance. Front Immunol 2018; 9: 2498.
    OpenUrl
  23. 23.↵
    1. Yu Y,
    2. Gutierrez E,
    3. Kovacevic Z,
    4. Saletta F,
    5. Obeidy P,
    6. Suryo Rahmanto Y, et al.
    Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19: 2689–26702.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Ndevahoma F,
    2. Mukesi M,
    3. Dludla PV,
    4. Nkambule BB,
    5. Nepolo EP,
    6. Nyambuya TM.
    Body weight and its influence on hepcidin levels in patients with type 2 diabetes: A systematic review and meta-analysis of clinical studies. Heliyon 2021; 7: e06429.
    OpenUrl
  25. 25.↵
    1. Becker C,
    2. Orozco M,
    3. Solomons NW,
    4. Schümann K.
    Iron metabolism in obesity: how interaction between homoeostatic mechanisms can interfere with their original purpose. Part I: underlying homoeostatic mechanisms of energy storage and iron metabolisms and their interaction. J Trace Elem Med Biol 2015; 30: 195–201.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Nikonorov AA,
    2. Skalnaya MG,
    3. Tinkov AA,
    4. Skalny AV.
    Mutual interaction between iron homeostasis and obesity pathogenesis. J Trace Elem Med Biol 2015; 30: 207–214.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Catalán V,
    2. Gómez-Ambrosi J,
    3. Rodríguez A, et al.
    Activation of noncanonical Wnt signaling through WNT5A in visceral adipose tissue of obese subjects is related to inflammation. J Clin Endocrinol Metab 2014; 99: E1407–E1417.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Ma W,
    2. Jia L,
    3. Xiong Q,
    4. Feng Y,
    5. Du H.
    The role of iron homeostasis in adipocyte metabolism. Food Funct 2021; 12: 4246–4253.
    OpenUrl
  29. 29.↵
    1. Frühbeck G.
    Obesity: aquaporin enters the picture. Nature 2005; 438: 436–437.
    OpenUrlPubMed
  30. 30.↵
    1. Alkhalifa H,
    2. Mohammed F,
    3. Taurin S,
    4. Greish K,
    5. Taha S,
    6. Fredericks S.
    Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy. Oncol Lett 2021; 21: 458.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords